Short Interest in UCB SA (OTCMKTS:UCBJY) Declines By 97.9%

UCB SA (OTCMKTS:UCBJYGet Free Report) saw a significant drop in short interest in January. As of January 15th, there was short interest totalling 100 shares, a drop of 97.9% from the December 31st total of 4,700 shares. Based on an average daily trading volume, of 19,300 shares, the short-interest ratio is presently 0.0 days.

UCB Trading Down 0.4 %

Shares of OTCMKTS:UCBJY traded down $0.40 during trading on Friday, hitting $98.76. 5,393 shares of the stock were exchanged, compared to its average volume of 24,078. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The company has a fifty day moving average price of $97.53 and a two-hundred day moving average price of $92.23. UCB has a 12-month low of $46.00 and a 12-month high of $100.66.

About UCB

(Get Free Report)

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

Recommended Stories

Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.